Midazolam Aguettant (Midazolam)

Midazolam enhances the activity of the neurotransmitter GABA at the GABA‑A receptor. By binding to an allosteric site, it increases the flow of chloride ions into neurons, hyper‑polarising the cell membrane and reducing neuronal excitability. This results in sedation, anxiolysis, muscle relaxation and anticonvulsant effects.

The dose of Midazolam Aguettant is set by the prescribing clinician based on the patient’s age, weight, clinical condition, route of administration and the desired depth of sedation. Dosage adjustments may be required for hepatic impairment, the elderly or when used with interacting medications.

Midazolam is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be used only when the potential benefit justifies the risk. Limited data are available for breastfeeding; the drug does pass into breast milk, so caution is advised and alternatives should be considered when possible.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Midazolam belongs to the benzodiazepine class and offers a rapid onset with a relatively short duration, making it useful for brief procedures. Compared with agents such as propofol, it has a lower risk of cardiovascular depression but may cause more pronounced amnesia. Its safety profile is well‑established, though interactions with other CNS depressants must be managed.

Midazolam Aguettant should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct light, moisture and extreme temperature fluctuations to maintain potency and sterility.

The medication is supplied as an injectable solution for intramuscular or intravenous injection. Administration is performed by a qualified healthcare professional, who selects the route and dose based on the clinical indication, patient condition and monitoring requirements.

The most serious adverse events include severe respiratory depression, profound hypotension and rare anaphylactic reactions. These risks are heightened when Midazolam is combined with other depressant drugs, in patients with compromised airway reflexes, or in those with significant organ dysfunction.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, those with acute narrow‑angle glaucoma, and individuals with severe respiratory insufficiency who are not intubated. Caution is also advised for patients with severe hepatic disease, myasthenia gravis, or a history of severe paradoxical reactions.